TP53
Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax
American Journal of Hematology | February 19, 2026 | Volume: 101 | Issue: 4 | Pages: 866-871
Post‐
FDA
Approval Experience With Momelotinib in
JAK
Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Perip
American Journal of Hematology | January 8, 2026 | Volume: 101 | Issue: 3 | Pages: 570-576